

**LISTING OF CLAIMS**

The following "Listing of the Claims" will replace all prior versions and all prior listings of the claims in the present application:

1. (Currently amended) A method for treating a solid cancerous tumor, which comprises administering to a mammal in need of such treatment an effective amount of DMXAA or a pharmaceutically acceptable salt ~~or ester~~-thereof and administering an effective amount of gemcitabine.
2. (Currently amended) A method for treating a solid cancerous tumor, which comprises administering to a mammal in need of such treatment an effective amount of DMXAA or a pharmaceutically acceptable salt ~~or ester~~-thereof and administering an effective amount of gemcitabine in a potentiating ratio.
3. (Currently amended) The method according to claim 1 or claim 2, wherein the DMXAA or pharmaceutically acceptable salt ~~or ester~~-thereof and the gemcitabine are administered concomitantly.
4. (Currently amended) A method for treating a solid cancerous tumor, which comprises administering to a mammal in need of such treatment an effective amount of DMXAA or a pharmaceutically acceptable salt ~~or ester~~ thereof and administering an effective amount of gemcitabine, wherein the DMXAA or pharmaceutically acceptable salt ~~or ester~~ thereof and the gemcitabine are administered sequentially.
5. (Canceled)
6. (Canceled)

7. (Currently amended) A composition comprising a combination of DMXAA or a pharmaceutically acceptable salt or ester thereof and gemcitabine.
8. (Currently amended) The composition according to claim 7 wherein the DMXAA or a pharmaceutically acceptable salt or ester thereof and the gemcitabine are present in a potentiating ratio.
9. (Canceled)
10. (Canceled)
11. (Currently amended) A pharmaceutical formulation comprising a combination of DMXAA or a pharmaceutically acceptable salt or ester thereof and gemcitabine in association with one or more pharmaceutically acceptable carriers therefor.
12. (Original) A pharmaceutical formulation according to claim 11 wherein the formulation is adapted for intravenous administration.
13. (Currently amended) The pharmaceutical formulation according to claim 11 or 12 wherein the DMXAA or pharmaceutically acceptable salt or ester thereof and the gemcitabine are present in a potentiating ratio.
14. (Canceled)
15. (Canceled)
16. (Currently amended) A process for the preparation of a pharmaceutical formulation which process comprises bringing into association a combination of DMXAA or a pharmaceutically acceptable salt or ester thereof and gemcitabine with one or more pharmaceutically acceptable carriers therefor.

17. (Currently amended) The process according to claim 16 wherein the DMXAA or pharmaceutically acceptable salt or ester thereof and the gemcitabine are present in a potentiating ratio.

18. (Canceled)

19. (Canceled)

20. (Currently amended) A kit comprising in association for separate administration DMXAA or a pharmaceutically acceptable salt or ester thereof and gemcitabine.

21. (Currently amended) The kit according to claim 20 wherein the DMXAA or pharmaceutically acceptable salt or ester thereof and gemcitabine are present in a potentiating ratio.

22. (Canceled)

23. (Canceled)

24. (Canceled)

25. (Canceled)

26. (Canceled)

27. (Canceled)